1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Transplant Diagnostics Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Transplant Diagnostics Market, by Product and Service
8.1.1 Instruments
8.1.1.1. Market Revenue and Forecast
8.1.2. Reagents and Consumables
8.1.2.1. Market Revenue and Forecast
9.1. Transplant Diagnostics Market, by Screening Type
9.1.1. Pre-Transplant
9.1.1.1. Market Revenue and Forecast
9.1.2. Post-Transplant
9.1.2.1. Market Revenue and Forecast
10.1. Transplant Diagnostics Market, by Organ Type
10.1.1. Kidney
10.1.1.1. Market Revenue and Forecast
10.1.2. Liver
10.1.2.1. Market Revenue and Forecast
10.1.3. Heart
10.1.3.1. Market Revenue and Forecast
10.1.4. Lung
10.1.4.1. Market Revenue and Forecast
10.1.5. Pancreas
10.1.5.1. Market Revenue and Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Product and Service
11.1.2. Market Revenue and Forecast, by Screening Type
11.1.3. Market Revenue and Forecast, by Organ Type
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Product and Service
11.1.4.2. Market Revenue and Forecast, by Screening Type
11.1.4.3. Market Revenue and Forecast, by Organ Type
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Product and Service
11.1.5.2. Market Revenue and Forecast, by Screening Type
11.1.5.3. Market Revenue and Forecast, by Organ Type
11.2. Europe
11.2.1. Market Revenue and Forecast, by Product and Service
11.2.2. Market Revenue and Forecast, by Screening Type
11.2.3. Market Revenue and Forecast, by Organ Type
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Product and Service
11.2.4.2. Market Revenue and Forecast, by Screening Type
11.2.4.3. Market Revenue and Forecast, by Organ Type
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Product and Service
11.2.5.2. Market Revenue and Forecast, by Screening Type
11.2.5.3. Market Revenue and Forecast, by Organ Type
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Product and Service
11.2.6.2. Market Revenue and Forecast, by Screening Type
11.2.6.3. Market Revenue and Forecast, by Organ Type
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Product and Service
11.2.7.2. Market Revenue and Forecast, by Screening Type
11.2.7.3. Market Revenue and Forecast, by Organ Type
11.3. APAC
11.3.1. Market Revenue and Forecast, by Product and Service
11.3.2. Market Revenue and Forecast, by Screening Type
11.3.3. Market Revenue and Forecast, by Organ Type
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Product and Service
11.3.4.2. Market Revenue and Forecast, by Screening Type
11.3.4.3. Market Revenue and Forecast, by Organ Type
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Product and Service
11.3.5.2. Market Revenue and Forecast, by Screening Type
11.3.5.3. Market Revenue and Forecast, by Organ Type
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Product and Service
11.3.6.2. Market Revenue and Forecast, by Screening Type
11.3.6.3. Market Revenue and Forecast, by Organ Type
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Product and Service
11.3.7.2. Market Revenue and Forecast, by Screening Type
11.3.7.3. Market Revenue and Forecast, by Organ Type
11.4. MEA
11.4.1. Market Revenue and Forecast, by Product and Service
11.4.2. Market Revenue and Forecast, by Screening Type
11.4.3. Market Revenue and Forecast, by Organ Type
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Product and Service
11.4.4.2. Market Revenue and Forecast, by Screening Type
11.4.4.3. Market Revenue and Forecast, by Organ Type
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Product and Service
11.4.5.2. Market Revenue and Forecast, by Screening Type
11.4.5.3. Market Revenue and Forecast, by Organ Type
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Product and Service
11.4.6.2. Market Revenue and Forecast, by Screening Type
11.4.6.3. Market Revenue and Forecast, by Organ Type
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Product and Service
11.4.7.2. Market Revenue and Forecast, by Screening Type
11.4.7.3. Market Revenue and Forecast, by Organ Type
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Product and Service
11.5.2. Market Revenue and Forecast, by Screening Type
11.5.3. Market Revenue and Forecast, by Organ Type
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Product and Service
11.5.4.2. Market Revenue and Forecast, by Screening Type
11.5.4.3. Market Revenue and Forecast, by Organ Type
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Product and Service
11.5.5.2. Market Revenue and Forecast, by Screening Type
11.5.5.3. Market Revenue and Forecast, by Organ Type
12.1. Thermo Fisher Scientific
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. F. Hoffmann-La Roche
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Bio-Rad Laboratories
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Immucor
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. CareDx
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Illumina
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Qiagen
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Abbott Laboratories
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Becton, Dickinson and Co
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. DiaSorin
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
14.1. About Us
14.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
